Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning-Reference-Cited by-同舟云学术

Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

Published:2015-07-24 Issue:20 Volume:121 Page:3709-3716
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Vaughn Jennifer E.¹²,Sorror Mohamed L.¹²,Storer Barry E.³⁴,Chauncey Thomas R.¹²⁵,Pulsipher Michael A.⁶⁷,Maziarz Richard T.⁸,Maris Michael B.⁹,Hari Parameswaran¹⁰,Laport Ginna G.¹¹,Franke Georg N.¹²,Agura Edward D.¹³,Langston Amelia A.¹⁴¹⁵,Rezvani Andrew R.¹¹,Storb Rainer¹²,Sandmaier Brenda M.¹²,Maloney David G.¹²

Affiliation:

1. Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle Washington

2. Division of Medical Oncology; Department of Medicine; University of Washington School of Medicine; Seattle Washington

3. Clinical Statistics Program; Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle Washington

4. Department of Biostatistics; University of Washington School of Public Health; Seattle Washington

5. Marrow Transplant Unit; VA Puget Sound Health Care System; Seattle Washington

6. Pediatric Blood and Marrow Transplant Program; Primary Children's Hospital; Salt Lake City Utah

7. Division of Hematology/Hematological Malignancies; Huntsman Cancer Institute; University of Utah School of Medicine; Salt Lake City Utah

8. Center for Hematologic Malignancies; Knight Cancer Institute; Oregon Health and Science University; Portland Oregon

9. Colorado Blood Cancer Institute; Denver Colorado

10. Division of Hematology and Oncology; Medical College of Wisconsin; Milwaukee Wisconsin

11. Division of Blood and Marrow Transplantation; Department of Medicine; Stanford School of Medicine; Stanford California

12. Division of Hematology; Oncology; and Hemostaseology; Department of Medicine; University of Leipzig; Leipzig Germany

13. Hematopoietic Stem Cell Program; Baylor University School of Medicine; Dallas Texas

14. Division of Hematology-Oncology; Emory University School of Medicine; Atlanta Georgia

15. Bone Marrow & Stem Cell Transplant Center; Winship Cancer Institute; Emory University; Atlanta Georgia

Funder

The National Heart, Lung, and Blood Institute of the National Institutes of Health

Mohamed L. Sorror is also supported by a Research Scholar Grant from the American Cancer Society

The Patient-Centered Outcomes Research Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29498/fullpdf

Reference38 articles.

1. Improvement of overall survival in advanced stage mantle cell lymphoma;Herrmann;J Clin Oncol.,2009

2. Recent advances in the management of mantle cell lymphoma;Rivera-Rodriguez;Curr Opin Oncol.,2013

3. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy;Khouri;Ann Oncol.,1999

4. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma;Evens;Br J Haematol.,2008

5. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma;Kasamon;Biol Blood Marrow Transplant.,2005

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mantle Cell Lymphoma;Reference Module in Biomedical Sciences;2023

2. Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies;Interdisciplinary Cancer Research;2023

3. The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy;Frontiers in Medicine;2022-12-06

4. Treatment Landscape of Relapsed/Refractory Mantle Cell Lymphoma: An Updated Review;Clinical Lymphoma Myeloma and Leukemia;2022-11

5. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience;Cancers;2022-05-27